EDSA
Edesa Biotech, Inc.
$10.99
+0.55%
$97.2M
No data for this timeframe.
Vol
Market Cap$97.2M
Cap SizeMicro Cap
Inst. Holders3 funds
Inst. Value$57.9K
Inst. Activity0 buys / 1 sells
Insider Activity9B / 0S
Insider Net $$250.8K
Reddit Sentiment50° Neutral
SEC Reports5
Press Releases1
Recent Activity
May 15, 2026
SEC
CEO Pardeep Nijhawan voluntarily requested to receive 90% of his monthly base salary in fully vested RSUs instead of cas
8-K — Impact 2/10
May 14, 2026
SEC
Edesa Biotech reported fiscal Q2 2026 results with a net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/s
8-K — Impact 4/10
May 14, 2026
SEC
Edesa Biotech reported Q2 2026 net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/share) a year ago, as R
PRESS-RELEASE — Impact 4/10
May 1, 2026
Insider
Nijhawan Pardeep sold 1,159 shares
Chief Executive Officer @ $0.00 ($0.00)
Apr 1, 2026
Insider
Nijhawan Pardeep sold 2,578 shares
Chief Executive Officer @ $0.00 ($0.00)
Mar 10, 2026
Insider
Nijhawan Pardeep bought 1,000 shares
Chief Executive Officer @ $6.60 ($6.6K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — EXIT
0 shares ($0.00)
Inst.
VANGUARD GROUP INC — DOUBLED
45,543 shares ($111.1K)
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$14.00 (Nov 2025)
Current $10.99
Low $9.00
Median $14.00
High $19.00
2 analysts
$9.00
$19.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 3, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 13, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.55 | $-0.87 — $-0.23 | -120% YoY | 2 |
| Next Q | $-0.56 | $-0.90 — $-0.23 | -77% YoY | 2 |
| Current FY | $-1.64 ▼ -10.7% | $-2.30 — $-0.97 | -29% YoY | 2 |
| Next FY | $-1.74 | $-2.79 — $-0.69 | -6% YoY | 2 |
Latest Reports
BULLISH
Press
6/10
Edesa Biotech announced an oral presentation of Phase 3 data for paridiprubart in acute kidney injury at the ERA Congres
May 19, 2026
NEUTRAL
8-K
2/10
CEO Pardeep Nijhawan voluntarily requested to receive 90% of his monthly base salary in fully vested RSUs instead of cas
May 15, 2026
NEUTRAL
8-K
4/10
Edesa Biotech reported fiscal Q2 2026 results with a net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/s
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $54.5K | DOUBLED |
| MORGAN STANLEY | $3.3K | TRIM |
| BANK OF AMERICA CORP | $74.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | Nijhawan Pardeep | A | $0.00 |
| Apr 1, 2026 | Nijhawan Pardeep | A | $0.00 |
| Mar 10, 2026 | Nijhawan Pardeep | BUY | $6.6K |
| Mar 5, 2026 | Nijhawan Pardeep | BUY | $39.0K |
| Mar 4, 2026 | Nijhawan Pardeep | BUY | $42.6K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
3 institutional holders with $57.9K total value (39,952 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 37,600 | $54.5K | 94.2% | DOUBLED +187.1% |
| 2 | MORGAN STANLEY | 2,300 | $3.3K | 5.6% | TRIM -50.0% |
| 3 | BANK OF AMERICA CORP /DE/ | 52 | $74.00 | 0.1% | DOUBLED +145.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 25,000 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 15,864 | 45,543 | +187.1% | $111.1K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 25,000 | — | $61.8K | 2025-Q3 |
| UBS Group AG | DOUBLED | 683 | 1,819 | +166.3% | $4.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 4 | 683 | +16975.0% | $1.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 22 | 54 | +145.5% | $109.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 40,944 | 16,591 | -59.5% | $40.5K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 31 | 4 | -87.1% | $10.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 40,944 | — | $69.6K | 2024-Q4 |
| UBS Group AG | DOUBLED | 4 | 31 | +675.0% | $52.00 | 2024-Q4 |
| MORGAN STANLEY | TRIM | 28 | 14 | -50.0% | $24.00 | 2024-Q4 |
9 unique insiders with 9 transactions. Net insider value: $250.8K ($250.8K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | Nijhawan Pardeep | Chief Executive Officer | A | 1,159 | $0.00 | $0.00 |
| Apr 1, 2026 | Nijhawan Pardeep | Chief Executive Officer | A | 2,578 | $0.00 | $0.00 |
| Mar 10, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 1,000 | $6.60 | $6.6K |
| Mar 5, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 10,000 | $3.90 | $39.0K |
| Mar 4, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 10,000 | $4.26 | $42.6K |
| Mar 3, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 10,000 | $3.63 | $36.3K |
| Mar 2, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 2,000 | $2.00 | $4.0K |
| Mar 2, 2026 | Nijhawan Pardeep | Chief Executive Officer | A | 10,016 | $0.00 | $0.00 |
| Feb 27, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 30,000 | $2.22 | $66.7K |
| Feb 26, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 20,571 | $1.58 | $32.5K |
| Feb 26, 2026 | Brooks Michael J | President | BUY | 2,000 | $1.57 | $3.1K |
| Feb 19, 2026 | Nijhawan Pardeep | Chief Executive Officer | A | 82,236 | $0.00 | $0.00 |
| Feb 2, 2026 | Nijhawan Pardeep | Chief Executive Officer | A | 11,168 | $0.00 | $0.00 |
| Jan 5, 2026 | Nijhawan Pardeep | Chief Executive Officer | A | 10,444 | $0.00 | $0.00 |
| Dec 1, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 8,766 | $0.00 | $0.00 |
| Nov 3, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 6,968 | $0.00 | $0.00 |
| Oct 2, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 5,908 | $0.00 | $0.00 |
| Sep 11, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 5,981 | $0.00 | $0.00 |
| Aug 1, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 6,802 | $0.00 | $0.00 |
| Jul 2, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 7,186 | $0.00 | $0.00 |
| Jun 2, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 7,644 | $0.00 | $0.00 |
| May 29, 2025 | Brooks Michael J | President | A | 207,201 | $0.00 | $0.00 |
| May 29, 2025 | Marshall Patrick | Director | A | 11,000 | $0.00 | $0.00 |
| May 29, 2025 | Olson Charles V | Director | A | 11,000 | $0.00 | $0.00 |
| May 29, 2025 | Sistilli Carlo | Director | A | 20,001 | $0.00 | $0.00 |
| May 29, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 263,200 | $0.00 | $0.00 |
| May 29, 2025 | MacDonald Sean Arthur | Director | A | 20,001 | $0.00 | $0.00 |
| May 29, 2025 | Chypyha Joan | Director | A | 11,000 | $0.00 | $0.00 |
| May 29, 2025 | Weiler Peter J. | Chief Financial Officer | A | 65,000 | $0.00 | $0.00 |
| May 29, 2025 | Liu Da David | Director | A | 5,501 | $0.00 | $0.00 |
| May 2, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 6,392 | $0.00 | $0.00 |
| Apr 1, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 5,784 | $0.00 | $0.00 |
| Mar 3, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 6,339 | $0.00 | $0.00 |
| Feb 12, 2025 | Marshall Patrick | Director | A | 41,666 | $1.92 | $80.0K |
| Feb 12, 2025 | Sistilli Carlo | Director | A | 10,416 | $1.92 | $20.0K |
| Feb 12, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 100 | $0.00 | $0.00 |
| Feb 3, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 8,264 | $0.00 | $0.00 |
| Jan 6, 2025 | Nijhawan Pardeep | Chief Executive Officer | A | 8,476 | $0.00 | $0.00 |
| Dec 2, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 6,420 | $0.00 | $0.00 |
| Nov 12, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 4,630 | $0.00 | $0.00 |
| Oct 30, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 326,560 | $0.00 | $0.00 |
| Oct 30, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 150 | $0.00 | $0.00 |
| Oct 2, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 3,300 | $0.00 | $0.00 |
| Sep 3, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 3,055 | $0.00 | $0.00 |
| Aug 1, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 3,317 | $0.00 | $0.00 |
| Jul 2, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 4,015 | $0.00 | $0.00 |
| Jun 3, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 4,785 | $0.00 | $0.00 |
| May 1, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 3,083 | $0.00 | $0.00 |
| Apr 1, 2024 | Nijhawan Pardeep | Chief Executive Officer | A | 3,253 | $0.00 | $0.00 |
| Mar 25, 2024 | Nijhawan Pardeep | Chief Executive Officer | BUY | 5,000 | $4.00 | $20.0K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 4.2/10.
NEUTRAL
8-K
2/10
CEO Pardeep Nijhawan voluntarily requested to receive 90% of his monthly base salary in fully vested
May 15, 2026
NEUTRAL
8-K
4/10
Edesa Biotech reported fiscal Q2 2026 results with a net loss of $4.2M ($0.49/share), wider than the
May 14, 2026
NEUTRAL
PRESS-RELEASE
4/10
Edesa Biotech reported Q2 2026 net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/sha
May 14, 2026
NEUTRAL
DEFA14A
3/10
Edesa Biotech, Inc. is holding its 2026 Annual General and Special Meeting where shareholders will v
Apr 3, 2026
BULLISH
8-K
8/10
Edesa Biotech announced positive Phase 3 data for its investigational anti-TLR4 antibody, paridiprub
Feb 24, 2026
Historical analyst distribution (last covering-analyst action Nov 2025): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$14.00 mean target (Nov 2025)
$9.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $10.99 |
| Target Low | $9.00 |
| Target Mean | $14.00 |
| Target Median | $14.00 |
| Target High | $19.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.55 | $-0.87 | $-0.23 | -120.0% | +0.0% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.56 | $-0.90 | $-0.23 | -76.6% | +0.0% | — | $0.0B | 0.0% | 2 |
| Current FY 2026-09-30 |
$-1.64 | $-2.30 | $-0.97 | -28.7% | -10.7% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-09-30 |
$-1.74 | $-2.79 | $-0.69 | -6.4% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.550 | |
| 7d ago | $-0.550 | |
| 30d ago | $-0.550 | |
| 60d ago | $-0.550 | |
| 90d ago | $-0.450 | -0.100 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 3, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 19, 2026
fda
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
<p>TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed
May 19, 2026
short_volume
Short Volume: EDSA — 64.7% short (0.4M / 0.5M)
Short: 352,739 | Exempt: 44,438 | TRF Vol: 545,021 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
<p align="left">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on d
May 12, 2026
earnings_calendar
EDSA Q2 2026 Earnings Scheduled — 2026-05-12
Apr 29, 2026
short_interest
FTD: EDSA — 129,961 shares ($1.9M) failed to deliver
Settlement: 20260429, Price: $14.26, FTD Value: $1,853,243.86, EDESA BIOTECH INC COM NEW
Apr 28, 2026
short_interest
FTD: EDSA — 87,480 shares ($1.0M) failed to deliver
Settlement: 20260428, Price: $11.17, FTD Value: $977,151.6, EDESA BIOTECH INC COM NEW
Mar 31, 2026
other
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients <pre>Select
Mar 26, 2026
earnings
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
<p>TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing h
Mar 25, 2026
short_interest
FTD: EDSA — 84,309 shares ($0.6M) failed to deliver
Settlement: 20260325, Price: $7.02, FTD Value: $591,849.18, EDESA BIOTECH INC COM NEW
Mar 20, 2026
short_interest
FTD: EDSA — 97,624 shares ($0.7M) failed to deliver
Settlement: 20260320, Price: $7.23, FTD Value: $705,821.52, EDESA BIOTECH INC COM NEW
Mar 19, 2026
short_interest
FTD: EDSA — 119,430 shares ($0.9M) failed to deliver
Settlement: 20260319, Price: $7.69, FTD Value: $918,416.7, EDESA BIOTECH INC COM NEW
Mar 18, 2026
short_interest
FTD: EDSA — 152,923 shares ($1.1M) failed to deliver
Settlement: 20260318, Price: $7.00, FTD Value: $1,070,461, EDESA BIOTECH INC COM NEW
Mar 5, 2026
short_interest
FTD: EDSA — 119,798 shares ($0.5M) failed to deliver
Settlement: 20260305, Price: $4.27, FTD Value: $511,537.46, EDESA BIOTECH INC COM NEW
Mar 4, 2026
short_interest
FTD: EDSA — 120,771 shares ($0.5M) failed to deliver
Settlement: 20260304, Price: $4.35, FTD Value: $525,353.85, EDESA BIOTECH INC COM NEW
Feb 25, 2026
short_interest
FTD: EDSA — 642,201 shares ($1.0M) failed to deliver
Settlement: 20260225, Price: $1.51, FTD Value: $969,723.51, EDESA BIOTECH INC COM NEW